GeneDx Holdings Corp.
NASDAQ:WGSMedical - Healthcare Information Services
+$1.52 today
- Market cap
- $1.56B
- Beta
- 1.97
- P/E (TTM)
- -21.8
- EPS (TTM)
- -$2.65
Volume 1.71M
Average 1.28M
WGS Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
GeneDx Holdings Corp.NASDAQ: WGS
Net Debt · Q2 FY2026 · quarter ended Jun 2026
Net debt rises 166.0% from a year ago
Net debt stood at $107.09M at the end of Q2 FY2026, up 166.0% from a year earlier and up 44.2% from the prior quarter.
Context
- Net debt amounted to 22.2% of total assets at the end of Q2 FY2026, up 13.6 pp from a year earlier.
- Net debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +166.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- 46.95M USD
- Year-over-year change
- +51.7%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.95M | +51.7% |
| FY2024 | 2024-12-31 | 30.96M | +54.1% |
| FY2023 | 2023-12-31 | 20.09M | +133.3% |
| FY2022 | 2022-12-31 | (60.27M) | +83.6% |
| FY2021 | 2021-12-31 | (367.72M) | — |
Net Debt vs competitors
How WGS compares with its peers on the latest reported figures
- WGS's Jun 2026 net debt of $107.09M is the 2nd highest of the 9 companies compared; the peer median is -$19.18M.
- Its year-over-year change of +166.0% is the highest of 9, against a peer median of +25.1%.
- Net debt amounts to 22.2% of total assets for WGS, versus a peer median of 17.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $302.83M | +17.8% | -3.5% | 22.4% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $107.09M | +166.0% | — | 22.2% |
| Mar 2026 | $87.1M | +32.4% | -11.9% | 12.9% | |
| Jun 2026 | $86.64M | +69.2% | +39.6% | 65.6% | |
| Mar 2026 | -$13.23M | +77.8% | — | 1.1% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | -$25.13M | +8.8% | — | 62.2% |
| Mar 2026 | -$27.04M | +57.6% | — | 4.9% | |
| Mar 2026 | -$34.81M | -31.0% | — | 10.7% | |
BLLNBillionToOne, Inc. | Jun 2026 | -$404.71M | -392.1% | — | 55.5% |
| Peer median (excluding WGS) | -$19.18M | +25.1% | -3.5% | 17.7% | |
Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 400.57M | 137.4M | 99.68M | 85.21M | 105M |
| Short-term Investments | 0 | 0 | 30.47M | 55.97M | 66.29M |
| Net Receivables | 26.56M | 43.34M | 32.82M | 37.63M | 74.37M |
| Inventory | 33.46M | 13.67M | 8.78M | 10.65M | 13.95M |
| Other Current Assets | 3.8M | 6.39M | 1.96M | 1.08M | 1.51M |
| Total Current Assets | 483.54M | 212.62M | 182.34M | 197.97M | 268.29M |
| Property, Plant & Equipment (Net) | 62.72M | 84.29M | 59.38M | 58.51M | 69.11M |
| Goodwill | 0 | 0 | 0 | 0 | 13.52M |
| Intangible Assets | 0 | 186.65M | 172.63M | 158.6M | 168.48M |
| Long-term Investments | 900K | 900K | 0 | 0 | 0 |
| Tax Assets | 0 | 54.32M | 0 | 0 | 46.48M |
| Other Non-current Assets | 6.93M | 6.48M | 4.41M | 4.31M | 3.32M |
| Total Non-current Assets | 70.55M | 332.64M | 236.42M | 221.41M | 301.9M |
| Total Assets | 554.09M | 545.26M | 418.76M | 419.38M | 570.19M |
| Account Payables | 44.69M | 46.02M | 10.24M | 7.95M | 2.46M |
| Short-term Debt | 3.42M | 10.87M | 497K | 0 | 8.95M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 473K | 40K | 0 | 0 | 0 |
| Other Current Liabilities | 52.7M | 67.08M | 30.88M | 30.42M | 67.86M |
| Total Current Liabilities | 101.28M | 144.3M | 58.82M | 54.82M | 108.91M |
| Long-term Debt | 11M | 6.25M | 52.69M | 51.91M | 86.95M |
| Deferred Tax Liabilities | 0 | 56.98M | 1.56M | 965K | 47.24M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 35.28M | 24.02M | 14.74M | 5.52M | (37.14M) |
| Total Non-current Liabilities | 64.71M | 147.26M | 131.92M | 119.32M | 153.1M |
| Total Liabilities | 165.99M | 291.56M | 190.74M | 174.13M | 262.01M |
| Common Stock | 24K | 38K | 2K | 2K | 3K |
| Retained Earnings | (575.44M) | (1.12B) | (1.3B) | (1.35B) | (1.37B) |
| Accumulated OCI | 0 | 0 | 425K | 830K | 936K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 388.1M | 253.71M | 228.02M | 245.25M | 308.18M |
| Total Debt | 32.85M | 77.13M | 119.77M | 116.17M | 151.95M |
| Net Debt | (367.72M) | (60.27M) | 20.09M | 30.96M | 46.95M |
GeneDx Holdings Corp.
NASDAQ:WGS
Intrinsic Alpha fair value
Locked
Current Price
$51.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.